Other brands, such as Naramig, Maxalt and Almogran, lag behind, according to the poll compiled by NOP Healthcare, which this month focuses on the crowded market for prescription-only drugs for migraine.
Almost all GPs were aware of Imigran – the first drug in the triptans therapy class to launch, more than a decade ago – with its promotional messages more likely to encourage GPs to prescribe it than rival brands.
More than 90 per cent had heard of Zomig, with 82 per cent aware of GSK’s Naramig. Just under a third of GPs said their prescribing of these brands, both available for around seven years, was likely to be affected positively by promotional messages.
Three-quarters of GPs described the information they had seen on Imigran as generally positive. Half had a similarly favourable impression of Zomig.
Naramig and Merck Sharp & Dohme’s Maxalt fared less well, with only two-fifths and one-third of GPs, respectively, describing communications seen on these products as generally positive.
The low positive mentions for the three other products – Lundbeck’s Almogran (14 per cent), Menarini’s Migard (5 per cent) and Pfizer’s challenger Relpax (2 per cent) – reflect the lower overall awareness shown by GPs for these brands.
NOP surveyed 200 GPs online via GP Net for Pharma Focus.
NOP Healthcare drug research and analysis director Gary King said: ‘Imigran benefited from its “first on the market” status.’
NEXT MONTH: Treatments for erectile dysfunction